Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in
participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received
first-generation EGFR-TKIs resistance along with T790M negative.